Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Scher

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
Urology|April 1, 1997
Assessment of hormone refractory prostate cancerD Newling, S D Fosså, L Andersson, et al.
Cancer Research|November 1, 1982
Phase I clinical trial and pharmacokinetics of 4'-carboxyphthalato(1,2-diaminocyclohexane)platinum(II)D P Kelsen, H Scher, N Alcock, et al.
The New England Journal of Medicine|June 2, 1988
Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urotheliumJ L Gabrilove, A Jakubowski, H Scher, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 1, 1997
Cigarette smoking and chromosome 9 alterations in bladder cancerZ F Zhang, X M Shu, C Cordon-Cardo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2001
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancerW K Kelly, T Curley, S Slovin, et al.
British Journal of Cancer|June 13, 2015
An analysis of the association between prostate cancer risk loci, PSA levels, disease aggressiveness and disease-specific mortalityJ Sullivan, R Kopp, K Stratton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 1999
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working GroupG J Bubley, M Carducci, W Dahut, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Urology|April 1, 1997
Assessment of hormone refractory prostate cancerD Newling, S D Fosså, L Andersson, et al.
Cancer Research|November 1, 1982
Phase I clinical trial and pharmacokinetics of 4'-carboxyphthalato(1,2-diaminocyclohexane)platinum(II)D P Kelsen, H Scher, N Alcock, et al.
The New England Journal of Medicine|June 2, 1988
Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urotheliumJ L Gabrilove, A Jakubowski, H Scher, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 1, 1997
Cigarette smoking and chromosome 9 alterations in bladder cancerZ F Zhang, X M Shu, C Cordon-Cardo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2001
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancerW K Kelly, T Curley, S Slovin, et al.
British Journal of Cancer|June 13, 2015
An analysis of the association between prostate cancer risk loci, PSA levels, disease aggressiveness and disease-specific mortalityJ Sullivan, R Kopp, K Stratton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 1999
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working GroupG J Bubley, M Carducci, W Dahut, et al.
Pageof 8